Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Stuart Handelsman

Nephrology Atlanta, GA Medical Doctor

NPI 1063444883 CMS profile 139269

980 Johnson Ferry Road, Suite 410, Atlanta, GA 30342

Open in the dashboard

General payments

$3,595

184 records reported · program years 2019–2021

Research payments

$678

Paid to them · 1 record reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$707,544 paid to institutions, not to them · program years 2019–2022

Through program year 2021, Stuart Handelsman of Atlanta, GA is reported in the CMS Open Payments database as having received $3,595 across 184 general payments and $678 in research payments paid to them. Separately, studies naming them as principal investigator received $707,544 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $718 38
2020 General $1,155 52
2019 General $1,722 94
2019 Research $678 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Handelsman
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Stuart Handelsman were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Stuart Handelsman Nephrology median Middle half National median
2019 $1,722 $236 $90–$588 $163
2020 $1,155 $135 $46–$364 $114
2021 $718 $202 $67–$551 $132
2022 $0 $242 $77–$695 $149
2023 $0 $254 $84–$766 $160
2024 $0 $300 $99–$852 $164
2025 $0 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Relypsa, Inc. $558 30 payments
  2. AstraZeneca Pharmaceuticals LP $518 24 payments
  3. OPKO Pharmaceuticals, LLC $319 26 payments
  4. Akebia Therapeutics Inc $312 14 payments
  5. Mallinckrodt Hospital Products Inc. $260 11 payments
  6. CHF Solutions, Inc $255 6 payments
  7. Otsuka America Pharmaceutical, Inc. $225 12 payments
  8. Amgen Inc. $200 9 payments
  9. Horizon Therapeutics plc $185 12 payments
  10. GlaxoSmithKline, LLC. $126 6 payments
  11. Other $637 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $3,529 177 payments
  2. Education $66 7 payments
Products named General payments · program years 2019–2021
  1. LOKELMA $501 23 payments
  2. Veltassa Hyperkalemia $430 21 payments
  3. Auryxia $312 14 payments
  4. Rayaldee $260 23 payments
  5. ACTHAR $260 11 payments
  6. Aquadex $255 6 payments
  7. KRYSTEXXA $185 12 payments
  8. Veltassa Hyperkalemia $128 9 payments
  9. BENLYSTA $126 6 payments
  10. JYNARQUE $116 5 payments
  11. Other $1,174 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. Eli Lilly and Company $678 1 payment

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record